Our Oncology Clinical Strategy is designed to transform survival
At AstraZeneca, we think differently about the underlying genetic causes of cancer. Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.
Introduction to our clinical strategy
Our clinical stratgy is designed to transform survival. We aim to combat cancer at all stages, but we know that the earlier we can detect and address cancer, the closer we may be to better outcomes.
Latest Oncology News
Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU
AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets
Calquence reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
Enhertu additional analyses further reinforce ground-breaking efficacy in patients with HER2-positive metastatic breast cancer
Explore our Oncology pillars
Veeva ID: Z4-40328
Date of preparation: November 2021